Gut bacteria and treatment outcomes in lymphoma
Official title: A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
Funded at New York University School of Medicine · NIH-11261179 · Data updated 2026-11-12
Seeing whether the mix of gut bacteria relates to treatment success and immune responses in people with diffuse large B‑cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 24, 2022 |
| Project end | January 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $700,559 |
| NIH project number | 5R01CA269617-05 |
| Project ID | NIH-11261179 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults newly diagnosed with untreated diffuse large B‑cell lymphoma who are starting standard therapy and can provide stool and blood samples.
✕Less likely to help
People with other cancer types, those who have already completed lymphoma treatment, or anyone unable to provide required stool or blood samples likely would not benefit from participation.
What this research studies
As a patient, you would provide stool samples before treatment, during therapy, and about a year after, and give weekly blood samples while on treatment. Researchers will sequence stool using 16S and full metagenomic shotgun methods to map bacterial communities and measure immune cell activity in blood. The team will follow roughly 300 patients to see who is in remission at 12 months and link those outcomes to microbiome patterns and immune markers over time. The work aims to find specific gut signatures tied to better or worse treatment responses.
Why it matters
Potential benefit: If successful, this could help predict who is more likely to respond to lymphoma treatment and point to microbiome-based ways to boost immunity.
How similar studies have gone: Prior studies have linked gut microbiome patterns to treatment response in several solid tumors, but applying this approach to diffuse large B‑cell lymphoma is relatively new.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Diefenbach, Catherine Sibyl — New York University School of Medicine
- Study coordinator: Diefenbach, Catherine Sibyl
Related research
Other NIH-funded projects on the same topics.
-
Investigating how gut bacteria affect lymphoma treatment outcomes and immune response
This study is looking at how the bacteria in your gut might affect how well treatment works for people with diffuse large B-cell lymphoma, and it hopes to find ways to personalize therapies based on your unique gut health.
-
Combining radiation, CAR‑T (CART‑19), and gut microbiome changes to treat B‑cell lymphoma
This project uses radiation, CART‑19 cell therapy, and a short course of oral vancomycin to try to improve outcomes for people with B‑cell lymphoma.
-
Combining radiation therapy, CART-19 therapy, and gut microbiome changes to treat lymphoma
This study is exploring a new way to treat lymphoma by using a combination of radiation therapy, a special immune treatment called CART-19, and an antibiotic to adjust the gut bacteria, all aimed at helping your body fight the cancer better.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.